EurekAlert! Cancer Research

News Releases

Updates every hour. Last Updated: 12-May-2025 16:09 ET (12-May-2025 20:09 GMT/UTC)

4-Mar-2025

Evidence-based strategies improve colonoscopy bowel preparation quality, performance, and patient experience

American Gastroenterological Association
Reports and Proceedings

Updated consensus recommendations by the U.S. Multi-Society Task Force on Colorectal Cancer (MSTFCRC) address optimizing bowel preparation quality for colonoscopy. Highlights include the use of low volume bowel preparation and the adjunctive use of simethicone. In recognizing bowel preparation adequacy rate as a quality measure, the authors recommend a “reasonable benchmark” of greater than or equal to 90% at both the level of individual endoscopists and at the level of the endoscopy unit.

4-Mar-2025

Clusters of metabolic dysfunction-associated steatotic liver disease for precision medicine

Deutsches Zentrum fuer Diabetesforschung DZD
Peer-Reviewed Publication

Almost one in three adults worldwide suffers from fatty liver disease, also known as metabolic dysfunction-associated fatty liver disease (MASLD). MASLD can lead to serious liver diseases such as cirrhosis and liver cancer and increases the risk of type 2 diabetes and heart disease. How the disease develops and how it affects the body varies.

Journal: Nature Reviews Gastroenterology & Hepatology

4-Mar-2025

People with intellectual disabilities less likely to participate in population screening

Radboud University Medical Center
Peer-Reviewed Publication

People with intellectual disabilities (ID) are significantly less likely to participate in population-based cancer screening than the general population, according to researchers from Radboudumc and academic collaborative Intellectual Disability and Health - Sterker op eigen benen in The Lancet Public Health.

Journal: The Lancet Public Health

4-Mar-2025

A new frontier in cancer therapy: The role of non-coding RNAs and oxidative stress

Compuscript Ltd
Peer-Reviewed Publication

A new review article published in Genes & Diseases explores the intricate relationship between non-coding RNAs and oxidative stress in cancer progression shedding new light on the mechanisms that drive tumor development. As cancer incidence continues to rise, particularly among younger populations, researchers are uncovering key molecular interactions that could transform the landscape of targeted therapies.

Journal: Genes & Diseases
Funder: Hengyang City Science and Technology Planning Project (Hunan, China), Scientific Research Project of Hunan Provincial Health Commission (China), Scientific Research Project of Hunan Provincial Education Department (China)

4-Mar-2025

Chinese Medical Journal article reveals the anticancer potential of poly ADP-ribose polymerase inhibitors

Chinese Medical Journals Publishing House Co., Ltd.
Peer-Reviewed Publication

Poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, a class of targeted anticancer therapies, prevent genetic repair mechanisms in cancer cells by competitively binding to the active site of PARP and limiting its activity. A new review study by researchers from Sichuan University, China, outlines the molecular mechanisms of PARP inhibitors and the potential for combination therapies comprising PARP inhibitors and other anticancer drugs to improve treatment outcomes against various cancers while limiting the adverse effects.

Journal: Chinese Medical Journal

4-Mar-2025

Alpha particle therapy emerges as a potent weapon against neuroendocrine tumours

Genomic Press
Peer-Reviewed Publication

A review in Brain Medicine unveils the potential of targeted alpha particle therapy (TAT) as an innovative and exciting breakthrough for neuroendocrine tumours (NETs). Unlike traditional beta-particle treatments, TAT delivers high-energy alpha particles to devastate tumour DNA with precision, offering hope for patients with resistant cancers. Published on 4 March 2025, this study highlights preclinical successes and clinical breakthroughs, positioning TAT as a game-changer in oncology amidst ongoing challenges.

Journal: Brain Medicine

3-Mar-2025

New insights into how cancer evades the immune system

Amsterdam University Medical Center
Peer-Reviewed Publication

Research into immunotherapy against cancer typically focuses on better recognition of cancer cells by the body's own immune system. Researchers at Amsterdam UMC and Moffitt Cancer Center have taken a different approach. They investigated how cancer affects the energy management of healthy T cells and showed for the first time that contact with chronic lymphocytic leukaemia (CLL) cells leads to a serious energy crisis in these cells. These findings are published today in Cellular & Molecular Immunology, building on a publication earlier this month in Blood Advances.

Journal: Cellular and Molecular Immunology

3-Mar-2025

Study uncovers genetic drivers of aggressive prostate cancer

University of California - Los Angeles Health Sciences
Peer-Reviewed Publication

Scientists from UCLA, the University of Toronto and the University of Melbourne have uncovered new genetic clues that explain why some prostate cancers remain slow-growing while others become life-threatening.

Journal: Cancer Discovery

3-Mar-2025

Rice’s Gustavsson receives NSF CAREER Award to investigate dynamics of gene regulation

Rice University
Grant and Award Announcement

Rice University’s Anna-Karin Gustavsson has been awarded a National Science Foundation (NSF) CAREER Award to advance her research on gene regulation dynamics. The five-year, $788,823 grant will support the development of innovative tools to visualize, quantify and analyze DNA organization and interactions in real time.

Funder: U.S. National Science Foundation

3-Mar-2025

NIH provides critical funding for pediatric clinical trials in diseases not prioritized by industry, study shows

Ann & Robert H. Lurie Children's Hospital of Chicago
Peer-Reviewed Publication

The National Institutes of Health (NIH) serves as an important source of funding for clinical trials in children, especially for diseases, such as cancer, that are not as highly prioritized in industry-sponsored clinical trials, according to a recent study published in The Journal of Pediatrics. The study evaluated how the number of pediatric clinical trials, as an indicator for industry and NIH research priorities, compared with the burden of childhood disease in the United States.

Journal: The Journal of Pediatrics